REBUZZI, SARA ELENA
 Distribuzione geografica
Continente #
EU - Europa 1.801
AS - Asia 363
NA - Nord America 234
SA - Sud America 40
AF - Africa 3
Totale 2.441
Nazione #
IT - Italia 1.726
US - Stati Uniti d'America 222
SG - Singapore 139
VN - Vietnam 90
CN - Cina 83
BR - Brasile 27
FI - Finlandia 23
FR - Francia 21
HK - Hong Kong 13
GB - Regno Unito 10
IN - India 7
AR - Argentina 6
DE - Germania 6
MX - Messico 6
ID - Indonesia 5
CA - Canada 4
JP - Giappone 4
TH - Thailandia 4
PH - Filippine 3
UZ - Uzbekistan 3
AL - Albania 2
AT - Austria 2
CL - Cile 2
CO - Colombia 2
IE - Irlanda 2
IR - Iran 2
RS - Serbia 2
SA - Arabia Saudita 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
GT - Guatemala 1
HR - Croazia 1
IQ - Iraq 1
JO - Giordania 1
KR - Corea 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
SY - Repubblica araba siriana 1
TR - Turchia 1
TW - Taiwan 1
UA - Ucraina 1
UY - Uruguay 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 2.441
Città #
Genoa 1.202
Vado Ligure 218
Rapallo 185
Genova 106
Singapore 64
Ashburn 56
San Jose 41
Ho Chi Minh City 32
Council Bluffs 29
Helsinki 21
Lauterbourg 21
Hanoi 15
Beijing 14
Hong Kong 11
Santa Clara 11
St Louis 10
Los Angeles 9
Bordighera 5
Da Nang 5
Orem 5
Haiphong 4
Hải Dương 4
São Paulo 4
Atlanta 3
Cardiff 3
Chicago 3
Frankfurt am Main 3
Rome 3
Thái Nguyên 3
Belgrade 2
Biên Hòa 2
City of London 2
Dublin 2
Fresno 2
Guangzhou 2
Houston 2
Lappeenranta 2
London 2
New York 2
Nuremberg 2
Parker 2
Poplar 2
San Juan 2
Tashkent 2
Tokyo 2
Toronto 2
Vienna 2
Amman 1
Bamberg 1
Bandung 1
Bari 1
Belford Roxo 1
Bengaluru 1
Bilaspur 1
Brampton 1
Brooklyn 1
Bueno Brandão 1
Buffalo 1
Burlington 1
Buíque 1
Bình Dương 1
Bình Phước 1
Bắc Ninh 1
Cabanatuan City 1
Cachoeirinha 1
Can Tho 1
Canindé de São Francisco 1
Centro Municipality 1
Charlotte 1
Chennai 1
Chiang Mai 1
Chlef 1
Concordia 1
Copenhagen 1
Curitiba 1
Dallas 1
Delhi 1
Denver 1
Des Moines 1
Elizabeth 1
Englewood 1
Franca 1
Guadalupe 1
Guarulhos 1
Guatemala City 1
Hsinchu 1
Huechuraba 1
Itapevi 1
Iztapalapa 1
Jakarta 1
Jeddah 1
Johannesburg 1
Joinville 1
Kapurthala Town 1
Kathmandu 1
Khon Kaen 1
Kyiv 1
Lagos 1
Lambari 1
Lanús 1
Totale 2.179
Nome #
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? 202
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 175
Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study). 116
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 116
Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review 109
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) 105
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223 100
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study 98
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) 98
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab 95
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study 95
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 94
Fusion 3D gross sampling method to overcome heterogeneity in clear cell renal cell carcinoma (ccRCC) and grading angiogenic versus immune signatures. 89
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 89
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 89
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study 85
Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18f-fdg uptake 73
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report 71
Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials 70
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 67
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 64
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 63
THE PROGNOSTIC ROLE OF THE IMMUNE TUMOR MICROENVIRONMENT IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH IMMUNOTHERAPY (Meet-URO 18 I-TME study) 60
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) 60
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 59
Prognostic models for patients with metastatic urothelial carcinoma: why use them? 56
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study 50
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis 47
Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with 223RaCl2: Ten Years of Clinical Experience 17
Totale 2.512
Categoria #
all - tutte 9.994
article - articoli 9.828
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.822


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 2 0 15
2021/202280 1 1 3 1 0 3 1 11 13 12 11 23
2022/2023216 13 15 7 26 23 19 9 30 31 6 37 0
2023/2024168 7 17 3 23 14 31 11 7 3 16 7 29
2024/2025595 53 42 15 30 64 56 44 115 32 24 64 56
2025/20261.410 149 179 265 120 155 64 170 53 143 112 0 0
Totale 2.512